Medtronic plc, (NYSE: MDT), a global leader in healthcare technology, today announced continued momentum for the Affera™ family of technologies for cardiac arrhythmia treatment, including promising ...
Findings from the AltaValve Early Feasibility Study suggest that patients with a leaky mitral valve have sustained clinical ...
A prespecified analysis of the NOAH-AFNET 6 trial investigated the impact of kidney function on cardiovascular outcome in ...
A new study from King’s College London has introduced a promising drug that could help save people during heart attacks by stopping one of the most dangerous problems: a sudden, deadly change in heart ...
Atrial fibrillation (AF) is a predominant risk factor for heart failure, even in patients with preserved left ventricular ejection fraction. Emerging evidence suggests the significance of right ...
TYLER – The CHRISTUS Health Louis and Peaches Owen Heart Hospital in Tyler is one of the first sites in the nation to enroll patients in the Boston Scientific OPTIMIZE trial, a groundbreaking study ...
HAYWARD, Calif. - Pulse Biosciences Inc. (NASDAQ:PLSE) announced today the enrollment of initial patients in its NANOPULSE-AF study, a pivotal clinical trial evaluating the company’s nPulse Cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results